Stockreport

Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets

Lyra Therapeutics, Inc.  (LYRA) 
PDF Partnership opens expanded opportunity for LYR-210 to address chronic rhinosinusitis, a disease affecting approximately 88 million adults in China WATERTOWN, Mass. & [Read more]